LOXL4 as a selective molecular marker in primary and metastatic head/neck carcinoma

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4567-4571

  Scola, Nina ^a   Görögh, Tibor ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

EGFR; Gene expression; Head and neck squamous cell carcinoma; LOXL4; Metastasis

Indexed keywords

DIGOXIGENIN; LYSYL OXIDASE LIKE 4 PROTEIN; MESSENGER RNA; MOLECULAR MARKER; PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGAR GEL ELECTROPHORESIS; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DENSITOMETRY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GASTROINTESTINAL MUCOSA; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; AMINO ACID OXIDOREDUCTASES; BLOTTING, NORTHERN; CARCINOMA, SQUAMOUS CELL; CHILD; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LARYNGEAL MUCOSA; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER;

EID: 78650239327     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hoffman HT, Karnell LH, Funk GF, Robinson RA and Menck HR: The National Cancer Data Base report on cancer of the head and neck. Arch Otolaryngol Head Neck Surg 124: 951-962, 1998.
2. Sundvall M, Karrila A, Nordberg J, Grénman R and Elenius K: EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. Expert Opin Emerg Drugs 15: 185-201, 2010.
3. Görögh T, Weise JB, Holtmeier C, Rudolph P, Hedderich J, Gottschlich S, Hoffmann M, Ambrosch P and Csiszar K: Selective upregulation and amplification of the lysyl oxidase like-4 (LOXL4) gene in head and neck squamous cell carcinoma. J Pathol 212: 74-82, 2007.
4. Weise JB, Rudolph P, Heiser A, Kruse ML, Hedderich J, Cordes C, Hoffmann M, Brant O, Ambrosch P, Csiszar K and Görögh T: LOXL4 is a selectively expressed candidate diagnostic antigen in head and neck cancer. Eur J Cancer 44: 1323-1331, 2008.
5. Sambrook J, Fritsch EF and Maniatis T: Molecular Cloning. A Laboratory Manual, 2nd edition. Cold Spring Harbor laboratory Press, Cold Spring Harbor, NY, 1989.
6. Holtmeier C, Görögh T, Beier U, Meyer J, Hoffmann M, Gottschlich S, Heidorn K, Ambrosch P and Maune S: Overexpression of a novel lysyl oxidase-like gene in human head and neck squamous cell carcinomas. Anticancer Res 23: 2585-91, 2003.
7. Lordick F, Krauß J and Jäger D: Tumor markers and biomarkers in squamous cell cancer of the head and neck. HNO 56: 881-885, 2008.
8. Pauli C, Munz M, Kieu C, Mack B, Breinl P, Wollenberg B, Lang S, Zeidler R and Gires O: Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas. Cancer Lett 193: 25-32, 2003.
9. Chaubal S, Wollenberg B, Kastenbauer E and Zeidler R: EpCAM: A marker for the detection of disseminated tumor cells in patients suffering from SCCHN. Anticancer Res 19: 2237-2242, 1999.
10. Ceruse P, Rabilloud M, Charrie A, Dubreul C and Disant F: Study of CYFRA 21-1, a tumor marker, in head and neck squamous cell carcinoma. Ann Otol, Rhin laryngol 114: 768-776, 2005.
11. Brockmann J, Nottberg H, Glodny B, Heinecke A and Senninger NJ: CYFRA 21-1 Serum analysis in patients with esophageal cancer. Clin Cancer Res 6: 4249-4252, 2000.
12. Deng YF, Chen P, LinYZ, Le JZ, Wu XL, Yu MQ, Zhuang PY and Gao MH: Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. J Laryngol Otology 117: 190-194, 2003.
13. Doweck I, Barak M, Uri N and Greenberg E: The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer 83: 1696-1701, 2000.
14. Zimmermann M, Zouhair A, Azria D and Ozsahin M: The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol 1: 11-17, 2006.
15. Baumann M and Krause M: Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72: 257-266, 2004.
16. Maurizi M, Almadori G, Ferrandina G, Ferrandina G, Distefano M, Romanini ME, Cadoni G, Benedetti-Panici P, Paludetti G, Scambia G and Mancuso S: Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74: 1253-1257, 1996.
17. Demiral AN, Sarioglu S, Birlik B, Sen M and Kinay M: Prognostic significance of EGF receptor expression in early glottic cancer. Auris Nasus Larynx 31: 417-424, 2004.
18. Nestor M, Ekberg T, Dring J, vanDongen GAMS, Wester K, Tolmachev V and Anniko M: Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay. Tumor Biology 28: 253-263, 2007.
19. Walther EK, Dahlmann N and Gorgulla HT: Tumor markers in the diagnosis and follow-up of head and neck cancer: Role of CEA, CA19-9, SCC, TK, and DTTPase. Head Neck 15: 230-235, 1993.
20. Schliephake H: Prognostic relevance of molecular markers of oral cancer - A review. Int J Oral Maxillofac Surg 32: 233-245, 2003.
21. Bron L and Monnier P: Molecular alterations in head and neck squamous cell carcinoma. Clin Otolaryngol 20: 291-298, 1995.
22. Grandis J and Tweardy D: Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53: 3579-3584, 1993.